AI Summary & Key Takeaways
AI InsightStatins and beta blockers may have positive effects on angiogenesis in HFrEF patients via increasing VEGF levels.
📌 3 Key Takeaways
Abstract
Objective: In this study, our aim was to investigate the clinical significance of VEGF, sVEGFR-1 in HFpEF patients. Materials and methods: Seventy-two participants enrolled in this cross-sectional case-control study including HFpEF patients (n = 41) and healthy (n = 31) subjects. Blood samples were collected and serum VEGF, sVEGFR-1 analysis, and transthoracic echocardiography were performed. Results and discussion: The average sVEGFR-1 level of HFpEF patient group was significantly higher than the control group (respectively 0.136 ng/L (0.04–0.34), 0.06 ng/L (0.01–0.25); p < 0.001). The average VEGF level of HFpEF patients using beta blocker was significantly higher than the HFpEF patients not using it (respectively 0.585 ± 0.194 ng/L; 0.349 ± 0.269 ng/L; p = 0.025). The average VEGF level of HFpEF patients using statins was significantly higher than the HFpEF patients without a medication (respectively 0.607 ± 0.099 ng/L; 0.359 ± 0.273 ng/L; p = 0.038). Conclusion: Our study is the first study demonstrating the relations among HFpEF, accompanying morbidities, VEGF and sVEGFR-1 levels. Statins and beta blockers may have positive effects on angiogenesis in HFrEF patients via increasing VEGF levels.
Özet
Amaç: Bu çalışmada, korunmuş ejeksiyon fraksiyonlu kalp yetmezliği (KEFKY) hastalarında VEGF, sVEGFR-1’in klinik önemini araştırmayı amaçladık. Gereç ve yöntem: Çalışmaya KEFKY hatalar (n = 41) ve sağlıklı (n = 31) insanlardan oluşan toplam 72 kişi dahil edildi. Kan örnekleri alındı, serum VEGF ve sVEGFR-1 analizleri ve transtorasik ekokardiyografi değerlendirmesi tüm katılımcılara yapıldı. Tartışma: Hasta grubunun ortalama sVEGFR-1 düzeyi kontrol grubuna göre anlamlı derecede yüksekti (sırasıyla 0,136 ± 0,060; 0,074 ± 0,050;